• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Benefits of PDT more far-reaching than previously expected


Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.